恩替卡韦联合和络舒肝胶囊治疗慢性乙型肝炎肝纤维化疗效及对肝功能、肝纤维化指标、炎性因子的影响  

The Effects of Entecavir Combined with Luoshu Liver Capsule on the Treatment of Chronic Hepatitis b Liver Fibrosis and Liver function,Liver Fibrosis Index and Inflammatory Factors

作　　者：管柏林 

机构地区：[1]梁山县人民医院,山东梁山272600

出　　处：《菏泽医学专科学校学报》2017年第3期53-56,共4页Journal of Heze Medical College

摘　　要：目的探讨恩替卡韦、和络舒肝胶囊治疗慢性乙型肝炎肝纤维化疗效及对肝硬化指标、肝功能;炎性因子的水平变化的影响。方法慢性乙型肝炎肝纤维化患者144例。随机分为治疗组与对照组,每组各72例,两组患者均根据病情,保肝、抗氧化、营养支持等常规治疗。治疗组:恩替卡韦0.5 mg/日,口服,联合和络舒肝胶囊1次5粒,每日3次,口服,3个月为一疗程,6个月后评价疗效及血清学变化。开始治疗第1天和6个月后抽晨起静脉血检测肝硬化指标、肝功能;炎性因子的水平。结果对照组治疗前后HA、C-IV水平变化,P<0.01;对照组治疗前后PC-III、LN、水平变化比较,P均<0.0005。治疗组治疗前后HA、PC-III、LN水平变化比较,P均<0.0005;治疗组治疗前后C-IV水平变化比较,P<0.005。两组治疗后HA水平变化比较,P<0.05;两组治疗后PC-III水平变化比较,P<0.001;两组治疗后LN水平变化比较,P<0.005;两组治疗后C-IV水平变化比较,P>0.05。对照组治疗前后ALT、AST水平变化比较,P均<0.0005;对照组治疗前后TBIL水平变化比较,P<0.005。治疗组治疗前后ALT、AST、TBIL水平变化比较,P均<0.0005。两组治疗后ALT水平变化比较,P<0.01;两组治疗后AST水平变化比较,P<0.0005;两组治疗后TBIL水平变化比较,P>0.05。对照组治疗前后血清IL-6、IL-8、INF-γ、IL-10、TNF-α水平变化比较,P均<0.0005。治疗组治疗前后血清IL-6、IL-8、INF-γ、IL-10、TNF-α水平变化比较,P<0.0005。两组治疗后血清IL-6、IL-8、INF-γ、IL-10、TNF-α水平变化比较,P<0.0005。对照组总有效率为66.67%,治疗组总有效率为86.11%。两组比较,P<0.01。结论恩替卡韦联合和络舒肝胶囊治疗慢性乙型肝炎肝纤维化能持续抑制病毒复制,促进肝功能恢复,取得了良好的疗效,值得临床推广与应用。Objective To investigate the curative effect of entecavir and luo shushu capsule on liver fibrosis in chronic hepatitis b and to the liver cirrhosis index and liver function; The effect of the horizontal change of inflammatory factors. Methods 144 patients with chronic hepatitis b liver fibrosis. Randomly divided into treatment group and control group, 72patients in each group, the two groups of patients were treated according to the condition, including routine treatment of liv- er, antioxidant and nutritional support. Treatment group： entecavir 0.5mg/day, oral, combined and luo shu liver capsule 5 pills /3 times/day, oral administration, 3 months for a course of treatment, 6 months after evaluation efficacy and serological change. The liver cirrhosis and liver function were detected after the first day and after 180 days. The level of inflammatory factors. Results The change of HA and C-IV levels in the control group was P〈0.01. Comparison of PC-III, LN, and horizontal changes before and after treatment in the control group, P〈0.0005. Compared with the changes of HA, PC-III and LN level before and after treatment group, P was 〈 0.0005. Comparison of C-IV level changes before and after treatment group treatment, P〈0.005. After treatment of the two groups, HA was compared with P〈0.05. Comparison of PC-III level chang- es after treatment of the two groups, P〈0.001; After treatment, the natural log of the two groups was compared with P〈 0.005. The changes in C-IV level were compared with P〉0.05. Comparison of ALT and AST levels in the control group was compared with P〈0.0005. Comparison of TBIL level before and after treatment was compared with P〈0.005. Compared with ALT, AST and TBIL before and after treatment, P 〈 0.0005. Comparison of ALT levels in the two groups after treatment, P〈 0.01. After treatment, the AST level change was compared, P〈0.0005. Comparison of TBIL level changes after treatment of two groups, P〉0.05. Comparison of serum IL-6, IL-8, INF- γ, IL-10 and TNF - alpha

关 键 词：恩替卡韦/治疗应用 和络舒肝胶囊/治疗应用 肝纤维化/治疗 肝硬化指标 肝功能 炎性因子 

分 类 号：R512.62[医药卫生—内科学] R446[医药卫生—临床医学]